Capital Raising

Filamon Limited

Preventing the switch of cancer from a generally well-controlled disease into a poorly-controlled disease

I am interested

Preventing the switch of cancer from a generally well-controlled disease into a poorly-controlled disease

I am interested

x

INDUSTRY

Medical

RAISING

A$3M

PRE-MONEY VALUATION

A$15M

OFFER PRICE

A$0.22

Investment Highlights Company Overview Transaction Overview Additional Information Team News

Transaction Summary

Filamon Limited

  • Raising A$3M

  • A$0.22 per share

  • Pre-Money Valuation of A$15M

I am interested

Investment Highlights


  • World-First Opportunity blocks three cancer functions that can switch to aggressive, treatment-resistant states

  • Two clinic-ready drug candidates: One completed Phase 1 study, One is already approved for another application and is to be repurposed for cancer. A third is currently undergoing advanced pre-clinical studies

  • Potential to transform the management of cancer, boosting survival outlook for hundreds of thousands of patients

Company Overview


  • Developing ground-breaking drug technologies

  • Ground floor investment opportunity

  • Board and Management with decades of corporate, drug development & clinical trialling experience

  • Compelling value propostiton

Potential to change the way cancer diagnoses are managed

Filamon is solving one of medicine’s greatest challenges – blocking the progression of cancer from a non-aggressive disease into an aggressive disease responsible for approximately 1 in 6 deaths.

Filamon’s world-first treatments can block three cell functions (recently identified by medical research) that switch cancers into an aggressive, treatment-resistant state. Filamon is developing three known drug molecules with the potential to block these functions.

Two of these drugs are clinic-ready: one has already completed a Phase 1 study in prostate cancer patients.

The other, in partnership with Henry Ford Health, a premier academic medical centre in Detroit, Michigan, USA, is a previously widely-used approved drug now repurposed for this specific anti-cancer purpose.

Filamon’s technologies could transform the management of cancer, boost the survival outlooks for hundreds of thousands of patients each year, and deliver very considerable returns on investment.

slide-image

Experienced board & management team

Filamon’s board and management team have decades of experience in biotechnology, fundraising and drug development.

Executive Chair and Interim CEO Dr Graham Kelly’s knowledge and networks can deliver the funds to develop life-saving medicines, combined with his corporate governance experience.

Backing our confidence are partnerships with eminent U.S. and Australian research institutions.

Initial opportunity to target prostate cancer management

For the proof-of-concept, Filamon is focusing on prostate cancers, a major and lucrative market opportunity responsible for an estimated 300,000 deaths each year.

Filamon is addressing one of medicine’s long-held ambitions: to see cancer become a manageable chronic disease like rheumatoid arthritis or heart disease.

Filamon’s three drug technologies have the ability to deliver on this ambition and are intended for use on a broad range of cancers, an enormous market opportunity.

slide-image

Filamon stands apart from other drug companies

We are focused on a particular point in the cancer disease process where the cancer cells unpredictably transform, changing from a controllable slow-growing state, into an aggressive state prone to metastasise (spread).

They then respond poorly to most current standard treatments – which for most patients, ultimately proves fatal.

Research shows two primary functions drive this switch. Until now, there were no known drugs that target these two functions. Today, Filamon has assembled two drug candidates that target both functions.

Transaction Overview


image

Filamon is seeking to raise up to A$3M on a pre-money valuation of A$15M

New Shares (pari passu with existing shares) are being issued at A$0.22

New Shares will account for 16.7% of the post-money issued capital

Use of funds

62.6%R&D

31.1%Working Capital

6.3%Transaction Costs

Additional Information


  • Company Presentations

Team


  • Management
  • Directors
  • Dr Graham Kelly

    Chairman & CEO

    iconicon
  • Dr Paul de Souza

    Non-Executive Director

    iconicon
  • Lisa Prasad

    Non-Executive Director

    iconicon
  • Dr Kieran Scott

    Chair, Scientific Advisory Board

    iconicon
  • Dr Philip Marshall

    Non-Executive Director

    iconicon
  • Cameron Jones

    CFO, Company Secretary

    iconicon
  • Dr Graham Kelly

    Chairman & CEO

    iconicon
  • Dr Paul de Souza

    Non-Executive Director

    iconicon
  • Lisa Prasad

    Non-Executive Director

    iconicon
  • Dr Philip Marshall

    Non-Executive Director

    iconicon

News


  • February 2023

    Senior Health Executive at Henry Ford Health Joins Board
    Read more
  • January 2023

    Second Exclusive Licence Elevates Filamon, to a Global Role in New Efforts to Tame Cancer
    Read more
  • December 2022

    New Australian biotechnology company aims to block the development of metastatic prostate cancer
    Read more

Want to learn more?

Fill in the expression of interest form below

    Thank you for your enquiry.
    We will be in touch as soon as possible.

    Speak to our investment team today

    +61 2 9993 4475